Suppression of colorectal cancer metastasis by nigericin through inhibition of epithelial-mesenchymal transition

Abstract

AIM: To evaluate the effect of nigericin on colorectal cancer and to explore its possible mechanism.

METHODS: The human colorectal cancer (CRC) cell lines HT29 and SW480 were treated with nigericin or oxaliplatin under the conditions specified. Cell viability assay and invasion and metastasis assay were performed to evaluate the effect of nigericin on CRC cells. Sphere-forming assay and soft agar colony-forming assay were implemented to assess the action of nigericin on the cancer stem cell properties of CRC cells undergone epithelial-mesenchymal transition (EMT).

RESULTS: Compared with oxaliplatin, nigericin showed more toxicity for the HT29 cell line (IC50, 12.92 ± 0.25 μmol vs 37.68 ± 0.34 μmol). A similar result was also obtained with the SW116 cell line (IC50, 15.86 ± 0.18 μmol vs 41.02 ± 0.23 μmol). A Boyden chamber assay indicated that a significant decrease in the number of HT29 cells migrating through polyvinylidene fluoride membrane was observed in the nigericin-treated group, relative to the vehicle-treated group [11 ± 2 cells per high-power field (HPF) vs 19.33 ± 1.52 cells per HPF, P < 0.05]. Compared to the control group, the numbers of HT29 cells invading through the Matrigel-coated membrane also decreased in the nigericin-treated group (6.66 ± 1.52 cells per HPF vs 14.66 ± 1.52 cells per HPF, P < 0.05). Nigericin also reduced the proportion of CD133⁺ cells from 83.57% to 63.93%, relative to the control group (P < 0.05). Nigericin decreased the number of spheres relative to the control group (0.14 ± 0.01 vs 0.35 ± 0.01, P < 0.05), while oxaliplatin increased the number of spheres relative to the control group (0.75 ± 0.02 vs 0.35 ± 0.01; P < 0.05). Nigericin also showed a decreased ability to form colonies under anchorage-independent conditions in a standard soft agar assay after 14 d in culture, relative to the control group (1.66 ± 0.57 vs 7 ± 1.15, P < 0.05), whereas the colony numbers were higher in the oxaliplatin group relative to the vehicle-treated controls (14.33 ± 0.57 vs 7 ± 1.15, P < 0.05). We further detected the expression of E-cadherin and vimentin in cells treated with nigericin and oxaliplatin. The results showed that HT29 cells treated with nigericin induced an increase in E-cadherin expression and a decrease in the vimentin expression relative to vehicle controls. In contrast, oxaliplatin downregulated the expression of E-cadherin and upregulated the expression of vimentin in HT29 cells relative to vehicle controls.

CONCLUSION: This study demonstrated that nigericin could partly reverse the EMT process during cell invasion and metastasis.

Key Words: Colorectal cancer; Nigericin; Cancer invasion; Metastasis; Epithelial-mesenchymal transition; CD133; E-cadherin; Vimentin

INTRODUCTION

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in men and the second most commonly diagnosed cancer in women[1], with a 5-year survival rate < 10% for patients with metastatic disease[2]. Despite the use of active targeted drugs for treatment of metastatic CRC, the cure rate has remained low in the past decade. Activating invasion and metastasis is the hallmark of cancer[3,4], during which malignant cells spread from the primary tumor to distant organs.

The pathogenesis of metastasis involves a series of steps, often termed the invasion and metastasis cascade, which includes the following: local invasion of the host stroma by tumor cells; detachment and embolization of tumor cell aggregates; extravasation of the tumor embolus; survival of tumor cells that are transported through the circulation and stop in the capillary bed; extravasation of the tumor embolus; proliferation of the tumor cells within the organ parenchyma, resulting in a metastatic focus; and reinitiation of these processes for the development of metastases. The first and decisive step of this process is the local invasion through the epithelial basement membrane, because it requires alteration in cell-cell and cell-matrix interactions, reconstruction of the extracellular matrix, remodeling of the cytoskeleton, and enhancement of cell modulation. Great progress has been made on the capacity for invasion and metastasis over the past decade with powerful novel research tools and refined experimental models becoming available. On the other hand, many critical regulatory genes have been identified.

Epithelial-mesenchymal transition (EMT), a transdifferentiation characterized by decreased epithelial markers such as E-cadherin and increased mesenchymal markers such as fibronectin, has become prominently implicated as a means by which transformed epithelial tumor cells acquire the ability to invade, resist apoptosis, and propagate[5-9]. More importantly, EMT has been shown to result in cancer cells with stem-cell-like characteristics that have a propensity to invade surrounding tissue and display resistance to chemotherapeutic interventions[6,10,11]. Nigericin is a potassium ionophore, which has been reported to be toxic to breast stem cells passing through EMT[12]. Lu et al[13] have reported that nigericin, like salinomycin, selectively inhibits Wnt1-mediated signaling in HEK293 cells at nanomolar concentrations.

In this study, we aimed to ascertain the specific activities of nigericin on human CRC cell lines. We selected CD133 as the marker of stem cells of CRC.

MATERIALS AND METHODS

Tumor cell preparation and cell culture

Human CRC cell lines, HT29 and SW116 were used. HT29 cells were cultured in McCoy’s 5A medium (Gibco, United States) with 10% fetal bovine serum (FBS). SW116 cells were cultured in RPMI 1640 medium with 10% FBS. The cells were cultured at 37 °C in a humidified atmosphere containing 5% CO₂.

Drugs and antibodies

Oxaliplatin and nigericin were both purchased from Sigma-Aldrich (St. Louis, MO, United States). Antibodies used for immunofluorescence staining and Western blotting were as follows: mouse anti-E-cadherin (Abcam Inc., Cambridge, MA, United States), mouse anti-vimentin (Abcam), mouse anti-CD133 (Abcam; used for Western blotting and immunocytochemistry), allophycocyanin-conjugated CD133 antibody (Miltenyi Biotec, Auburn, CA, United States) used for fluorescence-activated cell sorting (FACS), mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Abcam).

Analysis of cell viability

For assessment of cell viability in HT29 and SW116 cell lines under different treatments, cells growing at the exponential stage were plated in triplicate, in 96-well plates at a density of 2000 cells/well in a final volume of 100 μL. After incubation for 24 h, oxaliplatin, nigericin and dimethylsulfoxide (DMSO) control were added to each well of the plates. Cell viability was detected after 24 h using Cell Counting Kit 8 (DOJINDO, Japan). Absorbance for each well was read at 570 nm using a microplate reader. Growth inhibition was calculated as a percentage of the untreated controls. Experiments were done three or more times, often in triplicate, for each cell line, and IC₅₀ was determined using the four-parameter logistic model.

Cell migration and invasion

Analysis of cell migration was performed using Boyden chambers according to the manufacturer’s protocol (Becton Dickinson Labware, Bedford, MA, United States). For cell invasion study, the inserts of the chamber were prepared by coating the upper surfaces with Matrigel (BD Matrigel Matrix, Phenol Red-free). HT29 cells (3 × 10³) treated with DMSO control, oxaliplatin and nigericin in McCoy’s 5A medium without FBS were plated to the upper chamber. McCoy’s 5A with 20% FBS as chemoattractants were plated in the lower chamber of the 24-well pates. After 24 h, nonmigrating or noninvading cells were removed mechanically from the upper chamber using a cotton swab. Cells that migrated or invaded to the lower surface of the Transwell membrane were fixed in methanol for 30 min at 37 °C and stained with 0.05% crystal violet for 1 h. Cells were quantified by counting the number of stained nuclei in five individual fields by fluorescence microscopy, in triplicate.

Immunoblotting

Cell lysates were subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis, and the separated proteins were electrophoretically transferred to hydrophobic polyvinylidene fluoride (PVDF) membrane. After blocking in 5% skimmed milk solution for 2 h, the membranes were incubated with the primary antibodies diluted with anti-CD133, anti-E-cadherin, and anti-vimentin. Primary antibodies were detected with mouse secondary antibodies directed against human IgG and visualized with Odyssey Infrared Imaging System.

Real-time polymerase chain reaction

mRNA expression was determined by real-time polymerase chain reaction. RNA was extracted by using the TRIzol reagent (Invitrogen, Carlsbad, CA, United States) and reverse transcription was performed using Superscript II (Invitrogen) according to the manufacturer’s instructions. TaqMan reactions were done utilizing an ABI 7500 real-time quantitative polymerase chain reaction (PCR) system. For data analysis, raw counts were normalized to housekeeping gene average for the same time point and condition (ΔCt). The following primers were used in this study: CD133 forward CATCCACAGATGCTCCTAAGGC and reverse GCTTTATGGGAGTCTTGGTC; E-cadherin forward CGAGAGCTACACGTTCACGG and reverse GTGTCG AGGGAAAAATAGGCTG; vimentin forward CTCCTCCCCCTGTCACATAC and reverse TGATTGGCATCAGGACCGTTG. GAPDH was used as an internal control. Analysis was performed with the ΔΔCt method.

Flow cytometric analysis

HT29 and SW116 cells, after different treatments, were washed with PBS. Single cell suspensions were incubated with allophycocyanin (APC)-conjugated CD133 antibody (Miltenyi Biotec) for 30 min at 4 °C. Mouse IgG1-APC was selected as an isotype control body. 7-Aminoactinomycin was used to eliminate the dead cells. The labeled cells were detected by the BD FACSVantage Systems (Becton Dickinson) according to the manufacturer’s protocols. Gating was implemented on the basis of negative control staining profiles.

Colonosphere assay

McCoy’s 5A with B27 supplement (Invitrogen), 20 μg/mL epidermal growth factor (Invitrogen), 20 μg/mL fibroblast growth factor (Invitrogen), and penicillin-streptomycin served as the stem cell medium (SCM) for this experiment. HT29 cells, after the indicated treatments, were plated at a concentration of 200 cells/100 μL SCM in each of the 20 wells of a 96-well ultralow-attachment plate (Corning Life Sciences, CA, United States). Cells were supplemented with 100 μL SCM after 7 d of incubation and analyzed on day 14, and MTT solution (40 μL) was added to each well, and a colorimetric assessment was done. The average absorbance measurement for each group was used as an index of sphere number.

Soft agar colony-forming unit assays

We mixed 1.2% agar with 2 × McCoy’s 5A medium at a ratio of 1:1 to make a 0.6% agar growth medium solution. We pipetted 2 mL of the 0.6% growth medium mixture into each well of the six-well cell culture cluster (Corning Life Sciences). We avoided bubble formation and spread the mixture evenly by slowly rotating the plate. We allowed the 0.6% agar growth medium layer to harden for 30-40 min at room temperature in a sterile laminar flow hood. We determined the concentration of HT29 cells treated with DMSO control, oxaliplatin and salinomycin, and adjust the suspension to 5 × 10³ cells/mL in 0.3% agar diluted with PBS. We transferred 2 mL of the cell suspension to the 0.6% agar growth medium plate and cultured at 37 °C in the presence of 5% CO₂ for 14-21 d. We counted the number of colonies using a microscope.

Immunocytochemistry

Cells were directly sorted onto a glass slide, fixed with 4% paraformaldehyde, and stained with anti-E-cadherin, anti-CD133 and anti-vimentin monoclonal antibodies. Nuclei were identified by staining with 4’, 6-diamidino-2-phenylindole. Subcellular localizations were determined by using confocal microscopy. The fluorescence intensity of each region was analyzed by different people on three occasions.

Statistical analysis

All values were shown as mean ± SD. Statistical significance was calculated by t test unless otherwise stated (SPSS 17.0), considering P < 0.05 as statistically significant.

RESULTS

Nigericin inhibits tumor growth and invasion

We examined the in vitro effect of nigericin on tumor growth and metastasis. Compared with oxaliplatin, nigericin exhibited more toxicity for the HT29 cell line (IC₅₀, 12.92 ± 0.25 μmol vs 37.68 ± 0.34 μmol) (Figure 1A). We also obtained similar results with the SW116 cell line (IC₅₀, 15.86 ± 0.18 μmol vs 41.02 ± 0.23 μmol) (Figure 1B). We then checked whether nigericin had functional influence on the migratory and invasive capacity of CRC cells. After incubation for 24 h, nigericin induced a conspicuous reduction in the number of cells migrating through the PVDF membrane relative to the vehicle-treated controls [11 ± 2 cells per high-power field (HPF) vs 19.33 ± 1.52 cells per HPF, P < 0.05] (Figure 1C and D). It was surprising that oxaliplatin promoted the migration of CRC cells through PVDF membrane compared with the vehicle-treated controls (38 ± 2 cells per HPF vs 19.33 ± 1.52 cells per HPF, P < 0.05) (Figure 1C and D). Compared to the control group, the numbers of HT29 cells invading through the Matrigel-coated membrane also decreased in the nigericin-treated group (6.66 ± 1.52 cells per HPF vs 14.66 ± 1.52 cells per HPF, P < 0.05) (Figure 1E and F). Correspondingly, oxaliplatin treatment increased the number of HT29 cells invading through the Matrigel-coated membrane (28.66 ± 2.08 cells per HPF vs 14.66 ± 1.52 cells per HPF, P < 0.05) (Figure 1E and F).

Figure 1 Nigericin inhibits tumor growth and metastasis. A: Dose-response curves of HT29 cells treated with nigericin and oxaliplatin. Bars denote SD (n = 5); B: Dose-response curves of SW116 cells treated with nigericin and oxaliplatin. Bars denote SD (n = 5); C: Boyden chamber assays were done to compare the migratory capacities of HT29 cells treated with oxaliplatin and nigericin. Bars denote SD (n = 5); D: Also shown are phase-contrast images of HT29 cells migrating through the collagen membrane; E: Numbers of cells invading through the Matrigel-coated hydrophobic polyvinylidene fluoride membrane after treatment with the indicated compounds. Bars denote SD (n = 5); F: Images of HT29 cells migrating through the collagen membrane are also shown. DMSO: Dimethylsulfoxide; HPF: High-power field.

Effects of nigericin and oxaliplatin on expression of cancer stem cell marker

In order to complete subsequent experiments logically, we treated the HT29 cells with nigericin, oxaliplatin, and DMSO vehicle control for 3 d, and then replaced the culture medium containing drugs with normal McCoy’s 5A medium with 10% FBS for another 3 d incubation.

The stem cell marker prominin-1 (CD133), a pentaspan membrane protein, may not be the only marker, but it remains the most widely reported marker of cancer stem cells (CSCs) of CRC validated by different groups[14-18].

We further assessed the expression of CD133 on HT29 cells after treatment with nigericin and oxaliplatin using flow cytometry. The results demonstrated that nigericin reduced the positive rate of CD133 from 83.57% to 63.93%, relative to the control group (P < 0.05) (Figure 2A and B). In contrast, oxaliplatin treatment increased the expression of CD133 from 79.18% to 97.22%. In order to verify this result, we selected the SW116 cell line to repeat the experiment. Similarly, nigericin decreased the proportion of CD133⁺ cells from 4.55% to 0.31%; on the contrary, the expression rate of CD133 increased from 4.55% to 36.89% (Figure 2C and D). The data from real-time PCR, Western blotting, and immunocytochemistry indicated analogous results (Figure 2E-G).

Figure 2 Effects of nigericin and oxaliplatin on expression of cancer stem cell marker. A: Percentages of CD133⁺ cells after treatment of HT29 cells with nigericin and oxaliplatin. Bars denote SD; B: CD133 fluorescence-activated cell sorting (FACS) profiles are indicated for HT29 cell treatment with nigericin and oxaliplatin; C: Percentages of CD133⁺ cells after treatment of SW116 cells with nigericin and oxaliplatin. Bars denote SD; D: CD133 expression in SW116 cells after treatment was assayed with FACS; E: Immunofluorescence staining analysis of CD133 expression in HT29 cells after treatment; F: CD133 protein expression in HT29 cells after treatment was assayed with immunoblotting; G: Real-time polymerase chain reaction analysis of CD133 mRNA expression in HT29 cells. GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; DMSO: Dimethylsulfoxid.

Effect of nigericin and oxaliplatin on sphere- or colony-forming ability of CRC cells

To evaluate the ability to form colonies or spheres of HT29 cells treated with nigericin and oxaliplatin in the absence of serum and without attachment to culture plates[19]. We performed the sphere-forming assay and soft agar forming assay under serum-free conditions.

Differences between the nigericin and oxaliplatin groups were quantitated by plating a limited number of cells in each well of a low-attachment 96-well plate and evaluating the ability of HT29 cells to form colonospheres. Nigericin decreased the number of spheres relative to the control group (0.14 ± 0.01 vs 0.35 ± 0.01, P < 0.05), while oxaliplatin increased the number of spheres relative to the control group (0.75 ± 0.02 vs 0.35 ± 0.01, P < 0.05) (Figure 3A). Nigericin also showed a decreased ability to form colonies under anchorage-independent conditions in a standard soft agar assay after 14 d in culture, relative to the control group (1.66 ± 0.57 vs 7 ± 1.15, P < 0.05), whereas the colony numbers were higher in oxaliplatin group relative to the vehicle-treated controls (14.33 ± 0.57 vs 7 ± 1.15, P < 0.05) (Figure 3B and C).

Figure 3 Effects of nigericin and oxaliplatin on sphere- or colony-forming ability of cancer stem cells. A: Mean OD of sphere-forming HT29 cells after different treatments was assayed by methyl thiazolyl tetrazolium assay. Bars denote SD (n = 5); B: Numbers of colonies formed by HT29 cells after treatment in independent experiments. Bars denote SD (n = 5); C: Phase-contrast images of colonies formed in soft agar assays after treatment. DMSO: Dimethylsulfoxide; HPF: High-power field.

Up-regulation of E-cadherin and downregulation of vimentin in CRC cells after nigericin treatment

E-cadherin, encoded by the CDH1 gene, has dual functions in epithelial cells: as a cell-cell adhesion molecule and as a negative regulator of the canonical WNT signaling cascade; in particular, of its central mediator β-catenin. E-cadherin downregulation in mammalian cell systems is sufficient to trigger EMT[20]. Gupta et al[12] have reported that nigericin preferentially kills cells that have undergone EMT. In colorectal carcinomas, the embryonic EMT is activated during tumor invasion in disseminating cancer cells[21]. Characteristic of these cells is a loss of E-cadherin expression.

We detected the expression of epithelial marker (E-cadherin) and mesenchymal marker (vimentin) of cells treated with nigericin and oxaliplatin to ascertain the effects of diverse compounds on EMT.

As shown in Figure 4A and B, nigericin induced an increase in expression of E-cadherin and a decrease in expression of vimentin relative to vehicle controls. In contrast, the expression of E-cadherin in the cells treated with oxaliplatin was downregulated in contrast to vehicle controls; correspondingly, oxaliplatin treatment upregulated the expression level of vimentin. The data from real-time PCR showed similar results to immunocytochemistry and Western blotting (Figure 4C).

Figure 4 Upregulation of E-cadherin and downregulation of vimentin in cancer stem cells after nigericin treatment. A: Immunofluorescence staining analysis of treated HT29 cells using epithelial E-cadherin and vimentin staining; B: E-cadherin and vimentin expression in HT29 cells after treatment, assayed by Western blotting; C: Real-time polymerase chain reaction analysis of E-cadherin and vimentin mRNA expression in HT29 cells after treatment with dimethylsulfoxide (DMSO) vehicle, oxaliplatin and nigericin.

DISCUSSION

Significant progress has been made in understanding the molecular pathogenesis, diagnosis (hereditary and sporadic), and treatment of CRC. Despite the use of active targeted drugs for treatment of metastatic CRC in the past decade, and improvement of overall survival to nearly 2 years for nonresectable disease, the cure rate remains low[22].

5-Fluorouracil and oxaliplatin formed the mainstay of chemotherapeutic regimens for metastatic CRC. Oxaliplatin covalently binds to DNA, forming platinum-DNA adducts that cause prolonged G2 arrest and inhibition of growth, which lead to apoptotic cell death[23].

There is a large body of evidence that tumor cells that are resistant to chemotherapy represent a subpopulation of cells from the primary tumor, which is molecularly and phenotypically distinct. These cells are referred to by several names, including tumor-initiating cells, tumor-promoting cells, or more commonly, CSCs[16]. EMT is a highly conserved cellular process during embryonic development and a pathogenic feature in tumorigenesis[10,24].

During the process of EMT, epithelial cells lose the expression of E-cadherin and other components of epithelial cell junctions, adopt a mesenchymal cell phenotype, and acquire motility and invasive ability[25,26]. Furthermore, Mani et al[10] have induced EMT in nontumorigenic, immortalized human mammary epithelial cells (HMLEs) by ectopic expression of either the Twist or Snail transcription factors; these cells formed > 30-fold more mammospheres than did HMLEs infected with the corresponding control vector. They have concluded that the cells generated by EMT acquired yet another attribute of mammary stem cells. EMT, which enables cancer cell dissemination, also imparts a self-renewal capability to disseminating cancer cells.

There is no consensus as to the exact criteria that define a CSC, because markers might vary according to the tumor type. In our study, we suggested CD133 as a marker of tumor-initiating cells of CRC[14-18].

We evaluated the effect of nigericin and oxaliplatin on CRC cell lines, including invasion and metastasis, and growth on colon cancer spheres, or colonospheres. From the results of cell viability and flow cytometry assays, we could see that nigericin specifically targets CD133⁺ cell subpopulations within CRC cell lines. Moreover, nigericin induced inhibition of invasion and metastasis in HT29 cells. These effects may have been due to the fact that nigericin upregulated the expression of E-cadherin, while E-cadherin played an important role in cancer progression and EMT induction[27,28].

In a variety of human cancers, E-cadherin loss was closely related to poor prognosis, tumor progression, and metastasis[29,30]. Therefore, E-cadherin also could be a sign of drug efficiency of nigericin therapy in the future. Through analysis of the expression level of E-cadherin and vimentin, we may conclude that nigericin partly reverses EMT to affect the ability of CRC cells to invade and metastasize.

We further evaluated the effects of nigericin treatment on the characteristics of CSC phenotype. The nigericin treatment group had a decreased number of spheres or colonies relative to the vehicle control group. Our data led us to hypothesize further that nigericin treatment suppresses EMT-generating cells with the properties of stem cells. This hypothesis needs further studies using animal experiments and preclinical and clinical trials. Nigericin may prove to be the therapeutic strategy that is effective in patients with metastatic disease.

However, the molecular mechanisms involved in the effect of nigericin are poorly understood. Lu et al[13] have reported that nigericin, as a potassium ionophore, selectively inhibits Wnt1-mediated signaling in HEK293 cells.

The polyether ionophores like nigericin interfere with transmembrane potassium potential and promote mitochondrial and cell potassium efflux. We hypothesize that nigericin treatment antagonizes the Wnt signaling cascade, while Wnt signaling plays a crucial role in embryonic development and cancer[31-35]. Besides, certain other CSC markers and signaling pathways, including EZH2 and Hedgehog pathways may also play some important roles in the mechanism of nigericin treatment, and thus need further studies[36]. Further studies will focus on the relation between nigericin-induced EMT and Wnt signaling.

We showed for the first time that nigericin not only partly reversed the EMT process during cell invasion and metastasis, but also suppressed some of the CSC phenotypes generated by EMT. EMT plays a pivotal role in tumor invasion and metastasis; therefore, nigericin treatment may be of benefit in the future.

ACKNOWLEDGMENTS

We thank Pei-Qin Yu, Xue-Hua Chen for their technical assistance, and also thank the members of Shanghai Institute of Digestive Surgery, Shanghai for useful advice and guidance.

COMMENTS

Background

Despite therapeutic innovations, metastatic colorectal cancer (CRC) often has a poor prognosis and high mortality.

Research frontiers

Epithelial-mesenchymal transition (EMT) provides a new basis for understanding the progression of carcinoma towards dedifferentiated and more malignant states. The EMT program, which involves dissolution of adherens and tight junctions and a loss of cell polarity, dissociates the cells with epithelial cell sheets into individual cells that exhibit multiple mesenchymal attributes, including heightened invasiveness. EMT also generates cells with properties of stem cells. Nigericin has been reported recently to act as a selective breast cancer stem cell inhibitor. However, the effect of nigericin on CRC is unknown. In this study, the authors evaluated the anticancer effect of nigericin and its possible mechanisms.

Innovations and breakthroughs

Recent reports have highlighted the important role of EMT during the invasion-metastasis cascade. In particular, EMT can be seen at the edges of colon carcinomas that are invading adjacent tissues. This is the first study to report that nigericin could suppress CRC metastasis. Furthermore, our studies indicated the possible mechanisms of action of nigericin.

Applications

Through understanding the effect of nigericin on CRC cells, this study may indicate a future promising therapeutic strategy in the treatment of patients with metastatic colorectal carcinoma.

Terminology

E-cadherin is a hallmark of epithelial cell protein expression; vimentin is an intermediate filament component of the mesenchymal cell cytoskeleton. CD133 protein, a pentaspan cell surface receptor, is a putative CRC stem cell marker.

Peer review

The study investigated the antitumor activity of nigericin on CRC stem cells. The authors found that nigericin selectively targeted cancer stem cells, and inhibited EMT. It is well designed and well presented.